Study Links Residual Inflammation in Psoriasis Patients to Obesity and Fatty Liver Disease

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, inflammation can linger, leading to broader health implications such as obesity and cardiovascular and fatty liver disease. The findings of the studyopens in new tab/window in the Journal of Investigative Dermatologyopens in new tab/window (JID), published by Elsevier, could lead to more targeted and effective treatments that address the systemic aspects of psoriasis, beyond just the skin.

Systemic chronic inflammation has been implicated in several diseases that collectively represent the leading causes of disability and mortality worldwide, such as cardiovascular disease, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, and autoimmune and neurodegenerative disorders. Psoriasis, with its systemic inflammatory nature, high atherosclerosis burden, and frequent use of biologic drugs, could provide a valuable framework for studying residual inflammation. Prior to the present study, a comprehensive assessment of this concept was lacking.

Lead investigator Álvaro González-Cantero, MD, PhD, Department of Dermatology, Hospital Universitario Ramón y Cajal, and Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, says, "Patients with psoriasis have a reduced life expectancy due to an increased risk of cardiovascular disease. With the goal of better understanding this, we wanted to explore psoriasis as a systemic disease and its broader health implications."

This prospective observational study assessed residual inflammation in 209 psoriasis patients across three international cohorts (Spain, USA, and Sweden) who had achieved a ≤ 2 on the Psoriasis Area Severity Index (PASI) indicating no or mild psoriasis on stable biologic therapy. The key findings revealed that residual inflammation was present in 36.3% of these patients and was significantly linked to higher BMI, metabolic dysfunction-associated steatotic liver disease (MASLD), increased baseline systemic inflammation, and greater adipose tissue.

Dr. González-Cantero explains, "Our present study offers novel insights into psoriasis management by characterizing residual inflammation in patients undergoing biologic therapy across three independent international cohorts. This is particularly important now because it highlights that despite achieving good skin responses with biologics, a significant subset of patients, predominantly those with obesity (especially central obesity), higher baseline systemic and organ inflammation (as shown by PET/CT), increased subcutaneous and visceral adipose tissue, and markers of MASLD, continue to exhibit residual inflammation. This underscores a critical unmet need to address the systemic inflammatory burden beyond skin symptoms in psoriasis, potentially requiring interventions targeting obesity and metabolic dysfunction to improve overall patient outcomes."

Co-first author Alba Lecumberri, MD, Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, notes, "The strong association identified between residual inflammation and obesity, particularly central obesity and markers of hepatic inflammation, suggests that these patients may benefit from a more intensive cardiovascular risk assessment and management. This could involve closer monitoring of inflammatory markers like high-sensitivity C-reactive protein, as well as parameters related to liver health, by integrating lifestyle modifications or weight management strategies, potentially leading to earlier detection and intervention for associated comorbidities."

Commenting on the study, noted expert Michael Garshick, MD, MBBS, Department of Medicine, New York University Grossman School of Medicine, adds, “This research emphasizes the elevated cardiovascular risk in patients with psoriasis and that dermatologists (and rheumatologists) should be at the forefront of recognizing the cardiometabolic and cardiovascular concerns in the psoriasis patient population. An elevated high-sensitivity C-reactive protein testing can be used to further refine assessment of which psoriasis may be candidates for both lipid lowering and weight loss treatments.”

The investigators point out that further studies are needed to confirm their findings and better understand the long-term implications for patient management.

Co-first author Emilio Berna-Rico, MD, PhD, Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, concludes, “We believe this to be a relevant study for dermatology, as it has assigned the term 'residual inflammation' for the first time in psoriasis patients, taking into account the systemic inflammation of the disease. We hope that our results can pave the way for a broader approach in psoriasis research, which will allow us to mitigate the effects of systemic inflammation and improve patient management through the use of the innovative therapies available to us, in addition to educating patients on a healthy and anti-inflammatory lifestyle, in collaboration with other healthcare professionals.”

According to Joel M. Gelfand, MD, MSCE, Department of Dermatology, University of Pennsylvania Perelman School of Medicine, and JID Deputy Editor for Clinical Research & Epidemiology, “Despite excellent control of skin disease, a substantial percentage of psoriasis patients demonstrate residual systemic inflammation. These findings emphasize that just treating the skin signs of psoriatic disease is not sufficient, and patients often need additional approaches to lowering systemic inflammation.”

Notes for editors

The article is “Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts,” by Alba Lecumberri, Emilio Berna-Rico, Joel M. Gelfand, Axel Svedbom, Carlota Abbad-Jaime de Aragón, Fernando Neria, Diana Monge, Asunción Ballester- Martínez, Cristina Pindado-Ortega, María Castellanos-González, Mar Llamas-Velasco, Maria G. Barderas, Jorge Solís, Leticia Fernández-Friera, Pedro Jaén, Mona Stahle, Nehal N. Mehta, and Álvaro González-Cantero (https://doi-org.ucc.idm.oclc.org/10.1016/j.jid.2025.03.014opens in new tab/window). It appears online in the Journal of Investigative Dermatology, published by Elsevier.

The article is openly available for 60 days at https://www.jidonline.org/article/S0022-202X(25)00377-X/fulltextopens in new tab/window.

The full text of the article is also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window. Journalists wishing to interview the authors should contact Álvaro González-Cantero, MD, PhD, at [email protected]opens in new tab/window.

The Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative cohort was funded by the National Heart, Lung and Blood Institute Intramural Research Program in Bethesda, Maryland (HL006193-07). The Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis cohort was funded by competitive independent grants from the Instituto de Salud Carlos III, Spain (PI22/01847) and the National Psoriasis Foundation, USA (851908), and also by non-competitive investigator-initiated studies (LEO Pharma, Almirall, and Amgen). The DermaReg cohort was funded by competitive grants from Hudfonden, Psoriasisförbundet, and the US National Psoriasis Foundation.

About the Journal of Investigative Dermatology

The Journal of Investigative Dermatologyopens in new tab/window (JID) is the official journal of the Society of Investigative Dermatology and the European Society for Dermatological Research. JID publishes high impact reports describing original research related to all aspects of cutaneous biology and skin diseases. Descriptions of important findings that result from basic, translational, or clinical research are published. Clinical research can include, but is not limited to, interventional trials, genetics studies, epidemiology, and health services research. www.jidonline.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.